These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Kollmer J; Sahm F; Hegenbart U; Purrucker JC; Kimmich C; Schönland SO; Hund E; Heiland S; Hayes JM; Kristen AV; Röcken C; Pham M; Bendszus M; Weiler M Neurology; 2017 Aug; 89(5):475-484. PubMed ID: 28679600 [TBL] [Abstract][Full Text] [Related]
4. A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. Olsson M; Norgren N; Obayashi K; Plante-Bordeneuve V; Suhr OB; Cederquist K; Jonasson J BMC Med Genet; 2010 Sep; 11():130. PubMed ID: 20840742 [TBL] [Abstract][Full Text] [Related]
6. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015 [TBL] [Abstract][Full Text] [Related]
7. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder]. Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239 [TBL] [Abstract][Full Text] [Related]
8. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD. Teixeira AC; Saraiva MJ J Cell Mol Med; 2013 Mar; 17(3):429-35. PubMed ID: 23387326 [TBL] [Abstract][Full Text] [Related]
9. The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy. Castro J; Miranda B; Castro I; de Carvalho M; Conceição I Clin Neurophysiol; 2016 May; 127(5):2222-7. PubMed ID: 27072093 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of familial amyloid polyneuropathy]. Adams D; Samuel D; Slama M Presse Med; 2012 Sep; 41(9 Pt 1):793-806. PubMed ID: 22341949 [TBL] [Abstract][Full Text] [Related]
11. Tafamidis: a review of its use in familial amyloid polyneuropathy. Scott LJ Drugs; 2014 Aug; 74(12):1371-8. PubMed ID: 25022953 [TBL] [Abstract][Full Text] [Related]
13. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study. Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161 [TBL] [Abstract][Full Text] [Related]
14. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine. Obayashi K; Tasaki M; Jono H; Ueda M; Shinriki S; Misumi Y; Yamashita T; Oshima T; Nakamura T; Ikemizu S; Anan I; Suhr O; Ando Y Clin Chim Acta; 2013 Apr; 419():127-31. PubMed ID: 23462670 [TBL] [Abstract][Full Text] [Related]
15. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570 [TBL] [Abstract][Full Text] [Related]
16. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367 [TBL] [Abstract][Full Text] [Related]
17. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. Conceição I; González-Duarte A; Obici L; Schmidt HH; Simoneau D; Ong ML; Amass L J Peripher Nerv Syst; 2016 Mar; 21(1):5-9. PubMed ID: 26663427 [TBL] [Abstract][Full Text] [Related]
18. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Jiang X; Labaudinière R; Buxbaum JN; Monteiro C; Novais M; Coelho T; Kelly JW Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33597308 [TBL] [Abstract][Full Text] [Related]
19. Kidney and anemia in familial amyloidosis type I. Beirão I; Lobato L; Costa PM; Fonseca I; Mendes P; Silva M; Bravo F; Cabrita A; Porto G Kidney Int; 2004 Nov; 66(5):2004-9. PubMed ID: 15496172 [TBL] [Abstract][Full Text] [Related]
20. Family dynamics in transthyretin-related familial amyloid polyneuropathy Val30Met: Does genetic risk affect family functioning? Lopes A; Rodrigues C; Fonseca I; Sousa A; Branco M; Coelho T; Sequeiros J; Freitas P Clin Genet; 2018 Nov; 94(5):401-408. PubMed ID: 30019395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]